Zions Bancorporation, National Association’s Atea Pharmaceuticals AVIR Stock Holding History

Zions Bancorporation, National Association’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$595	Buy	+128	New	+$637	﹤0.01%	1518

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Zions Bancorporation, National Association's AVIR Position: Q2 2026 in Review

Zions Bancorporation, National Association opened a new position in Atea Pharmaceuticals (AVIR) in Q2 2026: 128 shares worth $595. The stake represents ﹤0.01% of the portfolio and ranks #1518 among its holdings.

125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

Zions Bancorporation, National Association held 128 shares of Atea Pharmaceuticals worth $595 as of Q2 2026.
Atea Pharmaceuticals was a new Zions Bancorporation, National Association position in Q2 2026.
Atea Pharmaceuticals made up ﹤0.01% of Zions Bancorporation, National Association's portfolio in Q2 2026, its #1518 holding.
125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Zions Bancorporation, National Association's 13F filing for Q2 2026, filed 31 Jul 2026.